Suppr超能文献

两性霉素B常规制剂与脂肪乳剂在一组中性粒细胞减少症患者中的药代动力学

Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.

作者信息

Ayestarán A, López R M, Montoro J B, Estíbalez A, Pou L, Julià A, López A, Pascual B

机构信息

Servicio de Farmacia, Hospital Vall d'Hebron, Barcelona, Spain.

出版信息

Antimicrob Agents Chemother. 1996 Mar;40(3):609-12. doi: 10.1128/AAC.40.3.609.

Abstract

The pharmacokinetics of amphotericin B administered in a conventional 5% dextrose (glucose) (5% D) solution and in a 20% fat emulsion formulation (Intralipid; 20% IL) were compared in 16 patients (mean age, 42 years [range, 18 to 70 years]) who had been hospitalized for hematological malignancies and with proven or suspected fungal infections. All of the patients received 50 mg (approximately 1 mg/kg of body weight per day) of amphotericin B daily in random order, either as a 50-ml lipid emulsion (20% IL) (group I) or in 500 ml of 5% D (group II). Five serum samples were taken during the 24 h after drug administration, and the levels of amphotericin B were measured by high-pressure liquid chromatography. Serum amphotericin B concentrations declined rapidly during the first 6 h, and subsequent measurements revealed a slow terminal elimination phase in both groups. The maximum serum amphotericin B concentration was significantly lower when the drug was administered in 20% IL (1.46 +/- 0.61 versus 2.83 +/- 1.17 micrograms/ml; P = 0.02). The area under the concentration-time curve from 0 to 24 h was also much lower in group I (17.22 +/- 11.15 versus 28.98 +/- 15.46 micrograms.h/ml). The half-life of the distribution phase was approximately three times longer in group I (2.92 +/- 2.34 h versus 0.64 +/- 0.24 h; P = 0.011). Conversely, the half-lives of the elimination phase were approximately equal in the two groups (11.44 +/- 5.18 versus 15.23 +/- 5.25 h). The mean residence times were also similar in both groups (19.41 +/- 11.13 versus 19.65 +/- 7.86 h). The clearance and the steady-state volume of distribution of amphotericin B in group I were about twice as great as those in group II (62.97 +/- 35.51 versus 33.01 +/- 14.33 ml/kg/h and 1,043.92 +/- 512.10 versus 562.32 +/- 152.05 ml/kg [P = 0.034], respectively). Finally, the volume of distribution in the central compartment was greater in group I than in group II (618.17 +/- 231.80 versus 328.19 +/- 151.71 ml/kg; P = 0.013), but there were no differences in the volume of distribution in the peripheral compartment (425.75 +/- 352.87 versus 234.14 +/- 75.92 ml/kg). These results suggest that amphotericin B has a different pharmacokinetic profile when it is administered in 20% IL than when it is administered in the standard 5% D form and that the main difference is due to a clear-cut difference in the steady-state volume of distribution, especially that in the central compartment.

摘要

在16例(平均年龄42岁[范围18至70岁])因血液系统恶性肿瘤住院且已证实或疑似真菌感染的患者中,比较了两性霉素B以传统5%葡萄糖(5% D)溶液和20%脂肪乳剂配方(英脱利匹特;20% IL)给药时的药代动力学。所有患者每天随机接受50mg(约1mg/kg体重)两性霉素B,要么作为50ml脂质乳剂(20% IL)(第一组),要么加入500ml 5% D中(第二组)。给药后24小时内采集5份血清样本,通过高压液相色谱法测定两性霉素B水平。两组中两性霉素B血清浓度在最初6小时内迅速下降,随后测量显示两组均有缓慢的终末消除期。当药物以20% IL给药时,血清两性霉素B的最大浓度显著较低(1.46±0.61对2.83±1.17μg/ml;P = 0.02)。第一组0至24小时浓度-时间曲线下面积也低得多(17.22±11.15对28.98±15.46μg·h/ml)。第一组分布相半衰期约为第二组的3倍(2.92±2.34小时对0.64±0.24小时;P = 0.011)。相反,两组消除相半衰期大致相等(11.44±5.18对15.23±5.25小时)。两组的平均驻留时间也相似(19.41±11.13对19.65±7.86小时)。第一组两性霉素B的清除率和稳态分布容积约为第二组的两倍(62.97±35.51对33.01±14.33 ml/kg/h以及1043.92±512.10对562.32±152.05 ml/kg [分别为P = 0.034])。最后,第一组中央室的分布容积大于第二组(618.17±231.80对328.19±151.71 ml/kg;P = 0.013),但外周室分布容积无差异(425.75±352.87对234.14±75.92 ml/kg)。这些结果表明,两性霉素B以20% IL给药时与以标准5% D形式给药时具有不同的药代动力学特征,主要差异在于稳态分布容积存在明显差异,尤其是中央室的差异。

相似文献

2
Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
Ann Pharmacother. 1995 Dec;29(12):1197-201. doi: 10.1177/106002809502901201.
4
Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients.
Int J Pharm. 2001 Feb 1;213(1-2):153-61. doi: 10.1016/s0378-5173(00)00663-3.
8
Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs.
J Vet Pharmacol Ther. 2018 Feb;41(1):e16-e21. doi: 10.1111/jvp.12446. Epub 2017 Aug 16.
10
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.
Antimicrob Agents Chemother. 1997 Jun;41(6):1275-80. doi: 10.1128/AAC.41.6.1275.

引用本文的文献

2
The Application of Hollow Fiber Cartridge in Biomedicine.
Pharmaceutics. 2022 Jul 18;14(7):1485. doi: 10.3390/pharmaceutics14071485.
6
Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections.
Infect Dis Ther. 2021 Mar;10(1):115-147. doi: 10.1007/s40121-020-00382-7. Epub 2021 Feb 1.
7
Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.
Pharmaceutics. 2020 Jan 1;12(1):29. doi: 10.3390/pharmaceutics12010029.
10
Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.
Clin Pharmacokinet. 2018 Feb;57(2):151-176. doi: 10.1007/s40262-017-0570-0.

本文引用的文献

2
Amphotericin B and its delivery by liposomal and lipid formulations.
J Clin Pharm Ther. 1993 Jun;18(3):147-53. doi: 10.1111/j.1365-2710.1993.tb00605.x.
4
Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard.
Antimicrob Agents Chemother. 1986 Apr;29(4):584-8. doi: 10.1128/AAC.29.4.584.
5
Unusual lipid structures selectively reduce the toxicity of amphotericin B.
Proc Natl Acad Sci U S A. 1988 Aug;85(16):6122-6. doi: 10.1073/pnas.85.16.6122.
7
Amphotericin B: delivery systems.
Antimicrob Agents Chemother. 1990 Mar;34(3):381-4. doi: 10.1128/AAC.34.3.381.
8
Amphotericin B: 30 years of clinical experience.
Rev Infect Dis. 1990 Mar-Apr;12(2):308-29. doi: 10.1093/clinids/12.2.308.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验